37 papers
Health economics explores the vital intersection where medical care meets financial reality, examining how resources are allocated, costs are managed, and value is determined in healthcare systems. This field goes beyond simple budgeting to investigate how policy decisions and pricing strategies impact patient access and public health outcomes. By analyzing the economic drivers behind medical treatments, researchers aim to create more sustainable and equitable systems for everyone.
On Gist.Science, we process every new preprint in this category directly from medRxiv, ensuring you have immediate access to the freshest research as it emerges. Our team transforms these complex studies into both plain-language overviews for general readers and detailed technical summaries for specialists, bridging the gap between raw data and actionable insight. Below are the latest papers in health economics, curated to help you navigate the evolving landscape of medical finance and policy.
This study analyzes clinical trial data to demonstrate that the Inflation Reduction Act has significantly reduced late-stage small molecule research and approvals in oncology, thereby refuting claims that the legislation has minimal negative impact on patient access to new treatments for serious conditions.
This study in Eastern Kasai, DRC, reveals that while a majority of households express a willingness to pay for primary health care, this willingness is highly sensitive to service costs and strongly influenced by socioeconomic factors and perceived quality, highlighting the urgent need for prepayment mechanisms and quality improvements to advance Universal Health Coverage.
A dynamic transmission model using recent UK epidemiological data demonstrates that implementing the 20-valent pneumococcal conjugate vaccine (PCV20) in children would significantly reduce disease burden and deaths while being cost-saving compared to PCV13 and PCV15, thereby supporting its timely adoption.
This early economic modelling study suggests that implementing a new care pathway to identify and treat children with monogenic obesity using pharmacotherapies like semaglutide is likely cost-effective for the NHS, although the findings are subject to uncertainty due to a lack of evidence for key parameters.
This study analyzes hospital price transparency data to reveal substantial geographic variation in commercial rates for interventional radiology procedures, with rates varying up to 8-fold across states and consistently lower in rural areas compared to urban ones.
This study utilizes a cost-of-goods-sold model to demonstrate that licensing and royalty fees are the primary drivers of manufacturing costs for mRNA-based cell and gene therapies, accounting for approximately 83% of total expenses and representing the most significant opportunity for policy-driven cost reduction.
This pre-trial health economic modelling study suggests that introducing antenatal biomarker screening for pre-eclampsia using PlGF and sFlt-1/PlGF ratios is potentially cost-effective in Tanzania, particularly when targeted at nulliparous women, with incremental cost-effectiveness ratios ranging from $184.15 to $1,011.78 per disability-adjusted life year averted.
This paper employs a mixed-methods policy simulation on Thailand's KhunLook digital health platform to demonstrate that a means-tested subsidy with a flat fee for the top 60% of users optimizes the trade-off between welfare, equity, and fiscal sustainability compared to full public provision or market-based pricing.
Using Global Burden of Disease 2023 data, this study reveals that approximately 6.22% of school-age children in Latin America and the Caribbean are affected by vision, hearing, or intellectual disabilities, with a high prevalence of mild-to-moderate conditions that, if addressed through cost-effective interventions, could yield significant social and economic returns.
This descriptive analysis of Vietnamese health insurance claims from 2018 to 2022 reveals that total Type 2 diabetes treatment expenditures nearly doubled, with medication costs constituting the largest share and spending heavily concentrated in Class I and II hospitals, underscoring the need to strengthen care at lower-level facilities to improve resource allocation.